Value of 18F-fluorodeoxyglucose PET/CT combined with pancreatic tumor markers in the diagnosis of recurrence and metastasis after surgery for early resectable pancreatic cancer

Abstract:

Objective：To investigate the value of 18F-fluorodeoxyglucose（18F-FDG） PET/CT combined with common serum pancreatic tumor markers in the diagnosis of recurrence and metastasis after surgery for early resectable pancreatic cancer. Methods：A retro－spective analysis was performed for the clinical data of 53 patients who were suspected of recurrence and metastasis after surgery for early resectable pancreatic cancer and underwent PET/CT，in order to explore the value of PET/CT combined with pancreatic tumor markers in the diagnosis of recurrence and metastasis after surgery for early resectable pancreatic cancer. Results：The combination group[PET/CT+carbohydrate antigen 19-9（CA19-9）+carbohydrate antigen 242（CA242）+carbohydrate antigen 50（CA50）] had a sen－sitivity of 97.83%，a specificity of 85.71%，an accuracy of 96.23%，a positive predictive value of 97.83%，and a negative predictive value of 85.71% in the diagnosis of recurrence and metastasis after surgery for early resectable pancreatic cancer. The combination group had a significantly higher sensitivity than the CA19-9 group，the CA242 group，and the CA50 group（P<0.05）. The combination group had significantly higher accuracy than the PET/CT group，the CA19-9 group，the CA242 group，and the CA50 group（P<0.05）. Serum CA19-9 level was positively correlated with maximum standardized uptake value of PET/CT（r=0.583，P=0.018）. Conclusion：18F-FDG PET/CT combined with common serum pancreatic tumor markers has high sensitivity，accuracy，and positive predictive value in the diagnosis of recurrence and metastasis after surgery for early resectable pancreatic cancer. It can identify recurrence and metastasis after pancreatic cancer surgery as early as possible to help patients get timely treatment.